Fukaishi Takahiro, Ishibashi Fumiaki
Department of Diabetes and Metabolism, Koganei Tsurukame Clinic, Tokyo, Japan.
Endoscopy Center, Koganei Tsurukame Clinic, Tokyo, Japan.
JMA J. 2025 Jul 15;8(3):809-816. doi: 10.31662/jmaj.2025-0011. Epub 2025 May 26.
Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist has shown significant promise in weight reduction and glycemic management in patients with type 2 diabetes (T2DM). However, there have been no reports evaluating the quality of life (QOL) in patients who switched from oral semaglutide to tirzepatide. This study prospectively investigated short-term changes in the QOL of these patients.
This study was a single-center, prospective observational study. Participants were patients with T2DM who switched from oral semaglutide to tirzepatide due to insufficient weight reduction between May 1, 2023, and December 31, 2023. The primary outcome was the change in the Diabetes Therapy-Related QOL (DTR-QOL) questionnaire scores from baseline to 3 months after switching. The changes in glycemic management and body weight were also assessed as secondary outcomes.
Eleven patients were enrolled in this study. The total DTR-QOL score was significantly improved 3 months after switching (from 58.0 ± 9.9 to 81.5 ± 11.2, p < 0.001). Four subscale domains were also significantly improved (p < 0.001, p < 0.001, p = 0.015 and p < 0.001, respectively). There were no significant changes in glycated hemoglobin levels and body weight 3 months after switching (from 6.8 ± 1.0% to 6.4 ± 0.8%, p = 0.068 and from 86.5 ± 19.6 kg to 84.2 ± 19.7 kg, p = 0.099, respectively).
Switching from oral semaglutide to tirzepatide potentially improves overall QOL in patients with T2DM in a short period of time. Further large cohort studies will reinforce the results.
替尔泊肽是一种新型的双重葡萄糖依赖性促胰岛素多肽和胰高血糖素样肽-1受体激动剂，在2型糖尿病（T2DM）患者的体重减轻和血糖管理方面显示出显著前景。然而，尚无关于从口服司美格鲁肽转换为替尔泊肽的患者生活质量（QOL）评估的报告。本研究前瞻性地调查了这些患者生活质量的短期变化。
本研究为单中心前瞻性观察性研究。参与者为2023年5月1日至2023年12月31日期间因体重减轻不足而从口服司美格鲁肽转换为替尔泊肽的T2DM患者。主要结局是转换后3个月时糖尿病治疗相关生活质量（DTR-QOL）问卷评分相对于基线的变化。血糖管理和体重的变化也作为次要结局进行评估。
本研究共纳入11例患者。转换后3个月时，DTR-QOL总分显著改善（从58.0±9.9提高至81.5±11.2，p<0.00l）。四个子量表领域也显著改善（分别为p<0.001、p<0.001、p=0.015和p<0.001）。转换后3个月时糖化血红蛋白水平和体重无显著变化（分别从6.8±1.0%降至6.4±0.8%，p=0.068；从86.5±19.6kg降至84.2±19.7kg，p=0.099）。
从口服司美格鲁肽转换为替尔泊肽可能在短时间内改善T2DM患者的总体生活质量。进一步的大型队列研究将强化这些结果。
